At the beginning of this year, I outlined five biotech predictions that could affect investors, and now that the first six months of the year are in the rearview mirror, it seems to be the perfect time to check in and see how I’m doing. Without further ado, here’s my report card -- warts and all.
No. 1: Celgene buys somebody -- Grade B
In January, I wrote, “Celgene Corporation (NASDAQ:CELG) will buy somebody. I don’t have any idea which company Celgene could buy in 2015, but the company’s getting flush with cash, and it’s been kicking a lot of tires over the past two years.”
Hey, check out all the research scientist jobs. Post your resume today!
